The value of serum M2BPGi concentration in the diagnosis of hepatocellular carcinoma
Main Article Content
Abstract
To determine serum M2BPGi cutoff values for the diagnosis of hepatocellular carcinoma (HCC) a cross-sectional study was conducted on 120 patients with hepatitis B virus (HBV) infection at Bach Mai Hospital from January 2025 to January 2026; there were 60 HCC patients and 60 chronic hepatitis B (CHB) patients. All patients underwent serum Mac-2 binding protein glycosylation isomer (M2BPGi) testing. The HCC group was predominantly male, aged over 60 years old, and exhibited significantly higher degrees of liver fibrosis and cirrhosis compared to the CHB group (p < 0.001). 45% of the HCC patients had M2BPGi levels at the 2+ grade, which was significantly higher than the 3.3% observed in the CHB group (p < 0.001). M2BPGi demonstrated high diagnostic performance for HCC with an area under the curve (AUC) of 0.854 (p < 0.001). At a cutoff index (C.O.I) ≥ 0.8, the sensitivity, specificity, and accuracy were 91.7%, 51.7%, and 71.7%, respectively. At a C.O.I ≥ 1.7, the sensitivity was 61.7%, the specificity was 88.3%, and the accuracy reached 75.0%.
Article Details
Keywords
Chronic hepatitis B, hepatocellular carcinoma, M2BPGi
References
2. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. Jama. 2023; 329(18): 1589-1602. doi:10.1001/jama.2023.5997.
3. Moon H-W, Park M, Hur M, Kim H, Choe WH, Yun Y-M. Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, galectin-3, and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases. Annals of laboratory medicine. 2018; 38(4): 331-337.
4. Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021; 56(7): 593-619. doi:10.1007/s00535-021-01788-x.
5. Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol. 2020; 12(5): 220-229. doi:10.4254/wjh.v12.i5.220.
6. Rizzo GEM, Cabibbo G, Craxì A. Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses. 2022; 14(5). doi:10.3390/v14050986.
7. Jun T, Hsu YC, Ogawa S, et al. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatol Commun. 2019; 3(4): 493-503. doi:10.1002/hep4.1321.
8. Mak LY, To WP, Wong DK, et al. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol. 2019; 25(11): 1398-1408. doi:10.3748/wjg.v25.i11.1398.
9. Lê Thị Hồng Hương. Đánh giá nồng độ M2BPGi ở bệnh nhân ung thư biểu mô tế bào gan. Hà Nội, Trường Đại học Y Hà Nội; 2024.
10. Lee IC, Lei HJ, Wang LC, et al. M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma. Liver Cancer. 2025; 14(1): 68-79. doi:10.1159/000540802.
11. Liu J, Hu HH, Lee MH, et al. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Sci Rep. 2017; 7(1): 14352. doi:10.1038/s41598-017-14747-5.
12. Dolgormaa G, Harimoto N, Ishii N, et al. Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling. Br J Cancer. 2020; 123(7): 1145-1153. doi:10.1038/s41416-020-0971-y.
13. Bui HH, Nguyen ST, Phan ST, Nguyen KM, Nguyen CD. Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B. Dig Dis Sci. 2023; 68(12): 4407-4417. doi:10.1007/s10620-023-08143-5.